Corcept Therapeutics Inc (CORT)
54.79
-1.66
(-2.94%)
USD |
NASDAQ |
Nov 14, 16:00
54.44
-0.35
(-0.64%)
After-Hours: 20:00
Corcept Therapeutics Free Cash Flow: 142.60M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | 142.60M |
| June 30, 2024 | 123.28M |
| March 31, 2024 | 124.70M |
| December 31, 2023 | 126.90M |
| September 30, 2023 | 154.37M |
| June 30, 2023 | 134.80M |
| March 31, 2023 | 110.63M |
| December 31, 2022 | 119.91M |
| September 30, 2022 | 135.92M |
| June 30, 2022 | 151.16M |
| March 31, 2022 | 177.36M |
| December 31, 2021 | 167.42M |
| September 30, 2021 | 152.70M |
| June 30, 2021 | 133.88M |
| March 31, 2021 | 142.80M |
| December 31, 2020 | 150.73M |
| September 30, 2020 | 164.41M |
| June 30, 2020 | 172.83M |
| March 31, 2020 | 144.83M |
| December 31, 2019 | 135.03M |
| September 30, 2019 | 108.12M |
| June 30, 2019 | 114.44M |
| March 31, 2019 | 104.44M |
| December 31, 2018 | 115.37M |
| September 30, 2018 | 118.82M |
| Date | Value |
|---|---|
| June 30, 2018 | 85.20M |
| March 31, 2018 | 85.42M |
| December 31, 2017 | 60.52M |
| September 30, 2017 | 40.16M |
| June 30, 2017 | 38.16M |
| March 31, 2017 | 24.37M |
| December 31, 2016 | 18.20M |
| September 30, 2016 | 17.88M |
| June 30, 2016 | 9.921M |
| March 31, 2016 | 8.199M |
| December 31, 2015 | 3.113M |
| September 30, 2015 | -2.47M |
| June 30, 2015 | -9.298M |
| March 31, 2015 | -18.19M |
| December 31, 2014 | -27.55M |
| September 30, 2014 | -33.85M |
| June 30, 2014 | -36.58M |
| March 31, 2014 | -36.78M |
| December 31, 2013 | -37.18M |
| September 30, 2013 | -38.28M |
| June 30, 2013 | -38.89M |
| March 31, 2013 | -37.58M |
| December 31, 2012 | -36.17M |
| September 30, 2012 | -33.66M |
| June 30, 2012 | -30.99M |
Free Cash Flow Range, Past 5 Years
110.63M
Minimum
Mar 2023
177.36M
Maximum
Mar 2022
143.31M
Average
142.70M
Median
Free Cash Flow Benchmarks
| Catalyst Pharmaceuticals Inc | 221.79M |
| ADMA Biologics Inc | 78.82M |
| Akebia Therapeutics Inc | -38.53M |
| Bioventus Inc | 29.05M |
| Alnylam Pharmaceuticals Inc | 16.06M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 73.83M |
| Cash from Investing (Quarterly) | -44.04M |
| Cash from Financing (Quarterly) | -21.09M |
| Free Cash Flow Per Share (Quarterly) | 0.6348 |
| Free Cash Flow to Equity (Quarterly) | 72.19M |
| Free Cash Flow to Firm (Quarterly) | 72.19M |
| Free Cash Flow Yield | 2.34% |